AJO

Audio Journal of Oncology - August 15th 2006

August 14, 2006 ⋅ Post a comment
Joan Houghton
Joan Houghton
Elizabeth Barrett-Connor
Elizabeth Barrett-Connor
Fran Balkwill
Fran Balkwill
Carl Christophe Schimanski
Carl Christophe Schimanski

Adjuvant Anastrozole for Patients With Breast Cancer: Long-Term Safety Results From the ATAC Study

REFERENCE: Lancet Oncol 2006;7:633
Joan Houghton, University College, London
The case for using aromatase inhibitors rather than tamoxifen as adjuvant endocrine treatment for postmenopausal patients with breast cancer was strengthened recently by the latest report from the ATAC (Arimidex, Tamoxifen, Alone or in Combination) study just published in the Lancet Oncology. Joan Houghton from London University explained to Sarah Maxwell how the safety of anastrozole has now been confirmed by five-year mature data from more than 6,000 patients.

Raloxifene for Cancer Prevention More Benefit Than Risk?

REFERENCE: N Engl J Med 2006;355:125
Elizabeth Barrett-Connor, University of California, San Diego
The findings of a study published in the New England Journal of Medicine shed new light on breast cancer chemoprevention by looking at the selective estrogen modulator raloxifene. Data on 10,000 women, who were recruited primarily to test the drug’s activity for preventing cardiovascular disease, showed a powerful effect in preventing breast cancer. The investigators suggest that in women at risk of osteoporosis, raloxifene may be a better agent for preventing breast cancer than tamoxifen.

Chemokines: Mediators of Invasion and Metastasis–New Targets for Ovarian Cancer Therapy?

REFERENCE: American Association for Cancer Research 97th Annual Meeting April 1-5, 2006, Washington DC. Education Session
Fran Balkwill, Barts Hospital, London
Chemo-attractant molecules called chemokines that direct the migration of immune cells around the body could become important new weapons in the cancer doctor’s therapeutic armory, according to Fran Balkwill who chaired an education session at the American Association for Cancer Research Annual Meeting. In difficult-to-treat diseases like ovarian cancer, chemokine modulation offers the possibility of contributing alternative targeted components to anticancer regimens.

Chemokines: Keys to Controlling Liver Cancer Metastasis?

REFERENCE: American Association for Cancer Research 97th Annual Meeting April 1-5, 2006, Washington DC. Abstract 406
Carl Christophe Schimanski, University of Mainz
The chemokine in the human body known as CXCR4 might be an omnipresent inductor of the metastatic process, according to Carl Schimanski who presented data on CXCR4 expression in hepatocellular carcinoma biopsies and related it to metastatic tumor properties in patients. He told the AACR conference that the recent availability of chemokine antagonists holds out the promise of modulating metastasis and extending patient survival.



Similar Interviews

  • Audio Journal of Global Health Issues: Dementia Prevention By Mid-Life Risk Score Assessment?">Audio Journal of Global Health Issues: Dementia Prevention By Mid-Life Risk Score Assessment?

    • Miia Kivipelto, Karolinska Institute, Stockholm REFERENCE: Lancet Neurology On Line: August 3rd, 2006 A 20 year study in Finland has

  • Virus Plus Cytokine Fight Primary and Metastatic Cancer

    • Paul Fisher REFERENCE: Meet the Professor Session, AACR 2007, Los Angeles PAUL FISHER, Columbia

  • Cardiovascular Medicine

    • Cardiologists and doctors whose patients have cardiovascular disease in any form receive up-to-date audio information via the audio journal of

    Post a comment

    Health For All 30 Years After Alma Ata? Mental Health And War»
    AliaIbrahim Zai, Egbert Sondorp, Gill Walt, Lucy Gilson, Ravi Narayan, Richard Horton, Vikram Patel, Willem Van De Put
    Two important symposia have been held in London to discuss healthcare issues posing significant dilemmas to world leaders in the 21st Century. "The Future of Primary Health Care" was attended by public health experts from around the Globe to assess the best options for improving primary health care in the future. It was held on the 30th anniversary of the Alma Ata Declaration made in 1977 which was intended as a blueprint for health provision and identified primary health care as the means through which the global goal of "Health for All" could be achieved. The second meeting, on "Mental Health in Fragile States", was held to raise the profile of mental health care in zones where conflict has taken place or is still happening. Analyses of the key issues and how to deal with them effectively were discussed by top experts from the London School of Hygiene and Tropical Medicine and associated organisations. Peter Goodwin attended both meetings and talked with some of the key speakers.
    LSHTM Audio News: British Association Special Edition»
    Astrid Fletcher, Jo Lines, Sari Kovats, Colin Sutherland, Michel Coleman
    Peter Goodwin hears from London School of Hygiene and Tropical Medicine experts speaking at the annual science festival of the British Association for the Advancement of Science held in Liverpool, September 6-10, 2008, and from recent scientific publications on: the health impact of global warming, a tropical virus reaching temperate zones, inequalities in cancer outcomes, how eating oily fish can save your eyesight, and free internet publishing scientific journals.
    Subscribe to Audio Medica Podcast